NanoKar Therapeutics Announces Formal Appointment
of Craig Mosman as Chief Executive Officer
Mosman to lead NanoKar’s next phase of translational validation, partner readiness, and strategic
collaboration for its ITAM optimization platform
Salt Lake City, UT — May 28, 2026 — NanoKar Therapeutics, an early-stage biotechnology
company developing intracellular signaling optimization technology for CAR-based cell
therapies, today announced the formal appointment of Craig Mosman, J.D., as Chief Executive
Officer.
Mosman will lead NanoKar’s partnership strategy and translational data priorities as the
company advances research from the University of Utah laboratory of Matt Bettini, Ph.D. toward
a partner-ready cell therapy platform. His appointment reflects NanoKar’s next phase of work:
building the evidence, relationships, and development path needed to position the company’s
ITAM optimization platform for potential commercialization with CAR-T, cell therapy, and
biopharmaceutical partners.
“I’ve been fortunate throughout my career to work closely with scientific discoveries at the point
where they begin to move from possibility to application,” Mosman said. “Dr. Bettini and his team
have developed a compelling platform, and I’m grateful for the opportunity to help advance his
work toward practical and rapid integration into existing and next-generation CAR-T programs.
The goal is to give this discovery the strongest possible path to reach more patients over time.”
Mosman brings experience across biotechnology, genomics, molecular biology, global health,
law, and entrepreneurship, with a track record of advancing early-stage technologies through
strategic partnerships. Before NanoKar, he co-founded Seek Labs, where he held senior
leadership roles spanning business development, legal affairs, intellectual property strategy, and
strategic collaborations.
“Craig’s experience sits precisely at the intersection of science and strategic execution,” said Dr.
Matt Bettini. “His ability to position emerging platforms for partnership makes him uniquely
suited to lead NanoKar at this stage.”
NanoKar’s proprietary ITAM optimization platform is designed to tune intracellular CAR signaling
to improve persistence, reduce toxicity, and expand the potential for efficacy in solid tumors. The
platform is intended to integrate into existing and next-generation CAR architectures without
requiring changes to antigen targeting, co-stimulation, or manufacturing workflows.
The company is advancing its preclinical platform, generating additional validation data, and
engaging potential licensing, co-development, and strategic partners. Its pipeline includes
programs across hematologic malignancies and solid tumors, including CD19, HER2, GD2,
Nectin4, EGFRvIII, and B7-H3-directed approaches.
About NanoKar Therapeutics
NanoKar Therapeutics, Inc. is a biotechnology company focused on developing next-generation
CAR-T cell therapies. Founded on breakthrough research from the University of Utah,
NanoKar’s proprietary platform technology is designed to overcome the key limitations of current
CAR-T therapies, including T-cell exhaustion and limited efficacy against solid tumors. The
company is committed to advancing its platform through strategic partnerships and clinical
development to bring transformative cell therapies to patients in need. For more information,
visit www.nanokartherapeutics.com.
Media Contact
NanoKar Therapeutics, Inc.
Email: Craig@nanokartherapeutics.com
##